PTGX Protagonist Therapeutics Inc

Price (delayed)

$124.67

Market cap

$8.14B

P/E Ratio

24.21

Dividend/share

N/A

EPS

$5.15

Enterprise value

$7.65B

?
Relative Growth: Rel. Growth: 96
Relative Strength: Rel. Strength: 78
Relative Valuation: Rel. Valuation: 59
Relative Profitability: Rel. Profitability: 99

Protagonist Therapeutics is a late-stage development biopharmaceutical company focused on peptide therapeutics. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with ...

Highlights
Protagonist Therapeutics's revenue has surged by 164% YoY and by 96% QoQ
PTGX's gross profit has soared by 163% YoY and by 95% from the previous quarter
The quick ratio has soared by 52% YoY but it has contracted by 9% from the previous quarter

Key stats

What are the main financial stats of PTGX

PTGX stock price

How has the Protagonist Therapeutics stock price performed over time
Intraday
-0.13%
1 week
-8.51%
1 month
-3.17%
1 year
47.07%
YTD
42.74%
QTD
-11.51%

Financial performance

How have Protagonist Therapeutics's revenue and profit performed over time
Revenue
$551.69M
Gross profit
$550.59M
Operating income
$323.1M
Net income
$342.26M
Gross margin
99.8%
Net margin
62%
The operating margin has soared by 183% from the previous quarter
The net margin has surged by 183% year-on-year and by 111% since the previous quarter
Protagonist Therapeutics's revenue has surged by 164% YoY and by 96% QoQ
PTGX's gross profit has soared by 163% YoY and by 95% from the previous quarter

Price vs fundamentals

How does PTGX's price correlate with its fundamentals

Growth

What is Protagonist Therapeutics's growth rate over time

Valuation

What is Protagonist Therapeutics stock price valuation
P/E
24.21
P/B
7.44
P/S
15
EV/EBIT
21.83
EV/EBITDA
21.63
EV/Sales
13.86
The equity has soared by 68% YoY and by 29% from the previous quarter
The P/B is 49% more than the 5-year quarterly average of 5.0 but 19% less than the last 4 quarters average of 9.2
Protagonist Therapeutics's revenue has surged by 164% YoY and by 96% QoQ
The stock's price to sales (P/S) is 85% less than its 5-year quarterly average of 102.0 and 77% less than its last 4 quarters average of 64.7

Efficiency

How efficient is Protagonist Therapeutics business performance
Protagonist Therapeutics's return on sales has surged by 176% YoY and by 112% QoQ

Dividends

What is PTGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PTGX.

Financial health

How did Protagonist Therapeutics financials performed over time
Protagonist Therapeutics's total assets has soared by 63% YoY and by 29% from the previous quarter
The current ratio has surged by 52% year-on-year but it has declined by 9% since the previous quarter
The debt is 99% smaller than the equity
The equity has soared by 68% YoY and by 29% from the previous quarter
The debt to equity has plunged by 50% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.